Open AccessSuccessful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon‐α
Author(s) -
Gazdaru Smaranda,
Perey Lucien,
Rosselet Anne,
Mathevet Patrice,
Chalandon Yves,
Vulliemoz Nicolas
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0381
Subject(s) - medicine , fertility preservation , nilotinib , myeloid leukemia , stem cell , oncology , hematopoietic stem cell transplantation , tyrosine kinase , stimulation , tyrosine kinase inhibitor , transplantation , immunology , cancer research , imatinib , fertility , biology , cancer , population , receptor , environmental health , genetics
The development of tyrosine‐kinase inhibitors (TKIs) has improved survival of patients with chronic myeloid leukemia (CML). Some patients may become resistant to TKIs and require hematopoietic stem cell transplant (HSCT) that is highly gonadotoxic. Fertility preservation with ovarian stimulation might be indicated but is challenging if patients need to remain on TKIs until HSCT because TKIs may compromise follicular development and response to ovarian stimulation. We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon‐α before and during ovarian stimulation for fertility preservation. Successful ovarian stimulation was performed, allowing cryopreservation of nine zygotes. Hematopoietic stem cell transplantation was performed, and at present, 3 years later, the patient presents a sustained major molecular response.